Comparison of Triptans

For the most current information on this topic please see Drugs for Acute Migraine.

Full update February 2021

The chart below compares triptans for acute migraines in adults, including dosing information. Use other information to help with medication selection: onset, half-life, bioavailability, efficacy, select side effects, drug interactions, and contraindications. For information on inpatient treatment of pediatric migraines, see our chart, Treatment of Pediatric Migraine. For patients with frequent migraines, see our chart, Drugs to Prevent Migraine in Adults.

--Information from Canadian product labelling unless otherwise noted.--

Drug/Costa

Dose (Adult)

Onset

Half-life

Bioavailability

Comments

TRIPTANS. Contraindications include ischemic or vasospastic heart disease, history of stroke or transient ischemic attack (TIA), cardiac arrhythmias, uncontrolled hypertension, peripheral vascular disease, ischemic bowel disease, other triptans or ergot derivatives within 24 hrs, and history of hemiplegic or basilar migraines (not a complete list). Number needed to treat (NNT) is ~5 for oral sumatriptan.2 Consider injection or nasal spray formulations for patients with severe nausea and vomiting, migraines that quickly intensify, or patients who awaken with migraine.5

Almotriptan oral tablet
(Axert [no longer available], generics)

$2.54/12.5 mg

6.25 to 12.5 mg (6.25 mg in mild to moderate liver impairment or severe kidney impairment). May repeat after 2 hrs. Max daily dose 25 mg (12.5 mg in mild to moderate liver impairment or severe kidney impairment).

0.5 to 2 hrs7

3 to 4 hrs

70%

Better tolerated and better 2-hr efficacy than oral sumatriptan.4

Contraindicated in severe liver impairment.

Not contraindicated with MAOIs.

Eletriptan oral tablet (Relpax, generics)

$10.09/40 mg

20 to 40 mg. May repeat after 2 hrs. Max daily dose 40 mg.

30 min8

4 hrs

50%

Better 2-hr efficacy and lower recurrence rate than oral sumatriptan.4

Contraindicated for use within 72 hrs of clarithromycin, itraconazole, ketoconazole, nelfinavir, and ritonavir (potent CYP3A4 inhibitors).

Contraindicated in severe liver impairment.

Not contraindicated with MAOIs.

Frovatriptan oral tablet (Frova, generics)

$13.50/2.5 mg

2.5 mg. May repeat after 4 hrs. Max daily dose 5 mg.

2 to 3 hrs7

26 hrs

20% to 30%

Longest half-life.

Better tolerated and lower recurrence rate than oral sumatriptan.4

Contraindicated in severe liver impairment.

Not contraindicated with MAOIs.

Naratriptan oral tablet
(Amerge, generics)

$6.64/2.5 mg

1 to 2.5 mg (start with 1 mg in mild or moderate kidney or liver impairment). May repeat once after 4 hrs. Max daily dose 5 mg (2 mg in mild or moderate kidney or liver impairment).

1 to 3 hrs7

5 to 8 hrs

~70%

Better tolerated than oral sumatriptan.4

Lower recurrence rate than oral sumatriptan.6

Contraindicated in severe kidney

(CrCl <15 mL/min) or severe liver impairment.

Not contraindicated with MAOIs.

Rizatriptan oral tablet
(Maxalt, generics)

Rizatriptan ODT (Maxalt RPD, generics)

$4/10 mg

5 to 10 mg (5 mg in hemodialysis, moderate liver impairment, or with propranolol). May repeat after 2 hrs. Max daily dose 20 mg (10 mg in hemodialysis, moderate liver impairment, or with propranolol).

0.5 to 2 hrs7

2 to 3 hrs

45%

Better 2-hr efficacy than oral sumatriptan.4

Orally disintegrating tablet has slower absorption than the oral tablet.

Contraindicated in severe liver impairment.

Contraindicated if MAOI used in the past two weeks.

Sumatriptan subcutaneous injection (Imitrex, generic)

$45.88/6 mg vial (Imitrex)
$38.37/6 mg pre-filled syringe

6 mg. May repeat after 1 hr. Max daily dose 12 mg.

10 to 15 min

2 hrs

96%

Fastest and most effective treatment, but has a higher rate of adverse effects.4

Contraindicated in severe liver impairment.

Contraindicated if MAOI used in the past two weeks.

Sumatriptan oral tablet
(Imitrex DF, generics)

$3.30/100 mg

50 or 100 mg. May repeat after 2 hrs. Max daily dose 200 mg.

30 min.

2 hrs

14%

Contraindicated in severe liver impairment. Not recommended in mild or moderate liver impairment.

Contraindicated if MAOI used in the past two weeks.

Sumatriptan nasal spray (Imitrex)

$17.91/20 mg

5, 10, or 20 mg. May repeat once after 2 hrs. Max daily dose 40 mg.

15 min

2 hrs

16%

Taste and nasal route not acceptable to some patients.1

Contraindicated in severe liver impairment. Not recommended in mild or moderate liver impairment.

Contraindicated if MAOI used in the past two weeks.

Suvexx oral tablet
(sumatriptan 85 mg/naproxen 500 mg)

$10.41/tab

One tablet. May repeat after 2 hrs. Max daily dose two tablets.

NA

2.2 hrs (S)/
19.9 hrs (N)

14% (S)/
95% (N)

Sumatriptan 50 mg plus naproxen

500 mg taken separately may be just as effective.3

Triptan/NSAID combo more effective and lasts longer than either alone.3

Contraindicated in severe kidney impairment (CrCl <30 mL/min).

Contraindicated in moderate or severe liver impairment. Not recommended in mild liver impairment.

Contraindicated if MAOI used in the past two weeks.

Zolmitriptan oral tablet (Zomig, generics)

Zolmitriptan ODT
(Zomig-ZMT, generics)

$2.96/2.5 mg

2.5 mg (half tablet for moderate or severe liver impairment). May repeat after 2 hrs. Max daily dose 10 mg.

45 min7

2.5 to
3 hrs

40%

Zolmitriptan oral tablet 5 mg single dose is not much more effective than 2.5 mg, but has more adverse effects.

Contraindicated if MAOI used in the past two weeks.

Zolmitriptan nasal spray (Zomig)

$16/5 mg

2.5 to 5 mg. May repeat after 2 hrs. Max daily dose 10 mg.

15 min9

3 hrs

41%

Zolmitriptan 5 mg nasal spray is more effective than 2.5 mg oral tablet.

Taste and nasal route not acceptable to some patients.1

Contraindicated if MAOI used in the past two weeks.

  1. Wholesale cost for dose specified (of generic, if available).

Canadian product monographs used in creation of this chart: almotriptan (August 2017); Relpax (May 2020); Frova (December 2012); Amerge (November 2016); Maxalt (April 2015); Imitrex (April 2018); Suvexx (February 2020); Zomig (December 2019).

Abbreviations: CrCl = creatinine clearance; MAOI = monoamine oxidase inhibitor; NA = not available; NSAID = nonsteroidal anti-inflammatory drug; ODT = orally disintegrating tablet.

References

  1. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: how to match patients and products. CNS Drugs 2003;17:431-47.
  2. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD008615.
  3. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev 2016;4:CD008541.
  4. British Association for the Study of Headache (BASH). National Headache Management System for Adults. 2019. http://www.bash.org.uk/downloads/guidelines2019/01_BASHNationalHeadache_Management_SystemforAdults_2019_guideline_versi.pdf. (Accessed December 8, 2020).
  5. Rothrock JF, Friedman DI. Triptan therapy for acute migraine. American Headache Society. https://americanheadachesociety.org/wp-content/uploads/2018/05/John_Rothrock_and_Deborah_Friedman_-_Triptans.pdf. (Accessed December 8, 2020).
  6. Gobel H, Winter P, Boswell D, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. Clin Ther 2000;22:981-9 [abstract].
  7. Fidler BD. Review of almotriptan: a 5-HT1B/1D agonist. P&T 2002;27:83-4,88,93-4.
  8. McCormack PL, Keating GM. Eletriptan: a review of its use in the acute treatment of migraine. Drugs 2006;66:1129-49.
  9. Amneal. Zomig nasal spray. https://zomig.com/what-is-zomig-nasal-spray/. (Accessed December 9, 2020).

Cite this document as follows: Clinical Resource, Comparison of Triptans. Pharmacist’s Letter/Pharmacy Technician’s Letter. February 2021. [370229]